Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Product sales	$ 1,989,988	$ 1,496,759	$ 3,842,005	$ 2,997,481
Cost of product sales	872,835	678,111	1,643,840	1,296,210
Gross profit	1,117,153	818,648	2,198,165	1,701,271
Operating expenses
Research and development	599,031	301,334	1,103,270	623,499
Sales and marketing	849,193	642,490	1,583,106	1,142,745
General and administrative	1,262,818	1,030,701	2,598,110	2,251,406
Total operating expenses	2,711,042	1,974,525	5,284,486	4,017,650
Operating loss	(1,593,889)	(1,155,877)	(3,086,321)	(2,316,379)
Other income (expenses)
Interest income	445	5,482	2,364	13,719
Interest expense, related party	(8,333)	0	(8,333)	0
Amortization of debt discount	(31,199)	0	(31,199)	0
Write-off of deferred financing costs	(86,736)	0	(86,736)	0
Total other income (expenses)	(125,823)	5,482	(123,904)	13,719
Net loss	(1,719,712)	(1,150,395)	(3,210,225)	(2,302,660)
Net loss attributable to non-controlling interest	363,629	156,016	627,314	276,799
Net loss attributable to BioLife Solutions, Inc.	$ (1,356,083)	$ (994,379)	$ (2,582,911)	$ (2,025,861)
Basic and diluted net loss per common share attributable to BioLife Solutions, Inc. (in dollars per share)	$ (0.11)	$ (0.08)	$ (0.21)	$ (0.17)
Basic and diluted weighted average common shares used to calculate net loss per common share (in shares)	12,568,041	12,144,776	12,512,949	12,122,667